Novo Nordisk Earnings Are Soon. It’s All About Weight-Loss Drug Sales.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...
MM&M1 小时
Medicaid spending on GLP-1s jumped more than 500% since 2019, per KFF
Only 13 states currently offer Medicaid coverage for GLP-1 drugs, but the number of prescriptions and overall spending has ...
Hims & Hers股票在"稳健的2024年第三季度"后维持TD Cowen买入评级
周二，TD Cowen维持了对Hims & Hers Health, Inc. (NYSE:HIMS)的积极立场，重申了买入评级，并将公司股票的目标价格定为$25.00。 这一背书是在2024年第三季度强劲的财务表现之后做出的。Hims & Hers报告销售额同比增长77%，调整后的EBITDA比华尔街预期高32%，达到5100万美元。 该公司对2024年第四季度的指引也超出预期，预计销售额同比增 ...
Truist维持HIMS股票"持有"评级，目标价23美元，Q3业绩超预期
周二，Truist Securities维持对Hims and Hers Health Inc. (NYSE:HIMS)股票的"持有"评级，目标价保持在23.00美元不变。该公司第三季度财务业绩超出预期，特别是在GLP-1相关产品的收入方面。 分析师指出，这些产品的收入显著高于预期，估计达到6000万至6500万美元，而在第三季度之前的预测为4000万美元。 Hims and Hers在第三季度的 ...
HealthDay on MSN3 小时
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.
Renal & Urology News4 小时
2010 to 2023 Saw Increase in GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...
ENDPOINTS NEWS4 小时
Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe ...
Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...
healthday5 小时
Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Dis ...
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...
Hims & Hers Health: Another Blowout Quarter Ignored
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Fish oil supplements might help reduce risk of cancer
Related ER visit often precedes a cancer diagnosis Medicaid covers GLP-1 weight-loss drugs in just 13 states Banning menthol ...